Supplementary material from "Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining"
Posted on 22.11.2018 - 05:07
Drug repurposing aims to find novel indications of clinically used or experimental drugs. Because drug data already exist, drug repurposing may save time and cost, and bypass safety concerns. Polypharmacology, one drug with multiple targets, serves as a basis for drug repurposing. Large-scale databases have been accumulated in recent years, and utilization and integration of these databases would be highly helpful for polypharmacology and drug repurposing. The Connectivity Map (CMap) is a database collecting gene-expression profiles of drug-treated human cancer cells, which has been widely used for investigation of polypharmacology and drug repurposing. In this study, we integrated the next-generation L1000-based CMap and an analytic Web tool, the L1000FWD, for systematic analyses of polypharmacology and drug repurposing. Two different types of anti-cancer drugs were used as proof-of-concept examples, including histone deacetylase (HDAC) inhibitors and topoisomerase inhibitors. We identified KM-00927 and BRD-K75081836 as novel HDAC inhibitors and mitomycin C as a topoisomerase IIB inhibitor. Our study provides a prime example of utilization and integration of the freely available public resources for systematic polypharmacology analysis and drug repurposing.
CITE THIS COLLECTION
Liu, Tsang-Pai; Hsieh, Yao-Yu; Chou, Chia-Jung; Yang, Pei-Ming (2018): Supplementary material from "Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining". The Royal Society. Collection. https://doi.org/10.6084/m9.figshare.c.4302764.v2
Select your citation style and then place your mouse over the citation text to select it.
Read the peer-reviewed publication